Back to Online Symposia Home Page
|
|
Program Description
There continue to be advances in the field of atypical antipsychotics and their application into clinical practice. Practicing clinicians need to be educated on the most recent advances in order to provide optimal care for their patients.
Learning Objectives
By participating in this
activity, you will be able to:
- Appreciate why antidepressant augmenting strategies are necessary.
- Understand why augmentation with atypical antipsychotics can be of value in dealing with treatment-resistant major depressive disorder.
- Be aware of atypical antipsychotic side effect profiles.
Who Will Benefit
This activity was designed to meet the continuing education needs of
psychiatrists and other physicians. Other mental health
professionals may find this activity informative and should check with their
state licensing and certification boards to determine if it meets their
continuing education requirements.
Your Distinguished Faculty
James W. Jefferson, MD
Distinguished Senior Scientist, Madison Institute of Medicine, Inc.; Director, Healthcare Technology Systems, Inc.; Clinical Professor of Psychiatry, University of Wisconsin
Faculty
Disclosures
James W. Jefferson, MD, has received grants and/or research support from Bristol-Myers Squibb Company, Forest, GlaxoSmithKline, Janssen, L.P., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Organon Pharmaceuticals USA, Inc., Pfizer Inc., Roche Laboratories Inc., Solvay Pharmaceuticals, UCB Pharma Inc., and Wyeth Pharmaceuticals Inc. He has also has received honoraria from Abbott, AstraZeneca, Bristol-Myers Squibb Company, Forest, GlaxoSmithKline, Eli Lilly and Company, Pfizer Inc., UCB Pharma Inc., Shire Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has served as a consultant for GlaxoSmithKline, Organon Pharmaceuticals, Shire Pharmaceuticals, and UCB Pharma Inc. He is the principal of Healthcare Technology Systems, Inc., and a stockholder in Bristol-Myers Squibb Company GlaxoSmithKline and SciClone He receives other financial or material support from the organizations
listed above from time to time.
|
Commercial
Support
Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Disclaimers
The content of this video
activity may include product information that is inconsistent with or outside
of the approved labeling for these products in the
United States. Before prescribing
any medication, you must familiarize yourself with the manufacturer's product
information.
To earn continuing
education credit, view this online course and complete the posttest and
evaluation provided. A passing score of 75% or more
must be achieved on the posttest. A link is provided within this online
activity to access the posttest and evaluation. You will have the option of
printing a CME Certificate for your records after submission of the
evaluation.
CME LLC, Bristol-Myers
Squibb Company and Otsuka America Pharmaceutical,
Inc. are not responsible for the speaker's statements, materials, acts or
omissions.
|
|
Continuing
Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
CME LLC designates this
educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Content Originally
Presented: March 1, 2008
Online Date: November 21, 2008
Credit Expiration Date: November 20, 2009
This activity is based on the symposium Augmentation in the Treatment of Major Depressive Disorder: The Role of Atypical Antipsychotics at the Psychiatric Congress
Regional Extension on March 1, 2008 in Arlington, Va. Participants who
attended the live symposium mentioned above cannot claim credit for this
activity.
|